Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3366MR)

This product GTTS-WQ3366MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Canine B-cell lymphoma research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Caninized
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3366MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ9926MR IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA KB-004
GTTS-WQ6412MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CT-011
GTTS-WQ8781MR IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IBI-306
GTTS-WQ14564MR IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA aCD1919
GTTS-WQ14762MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SGN-35
GTTS-WQ5177MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CAT-354
GTTS-WQ2538MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 477
GTTS-WQ8493MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA hu1124
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW